Scarica l'app Stockscreener
52.95
0.26%
-0.14
Dopo l'orario di chiusura:
52.97
0.02
+0.04%
Precedente Chiudi:
$53.09
Aprire:
$53.09
Volume 24 ore:
2.20M
Relative Volume:
1.04
Capitalizzazione di mercato:
$10.17B
Reddito:
$2.95B
Utile/perdita netta:
$523.88M
Rapporto P/E:
19.68
EPS:
2.69
Flusso di cassa netto:
$620.18M
1 W Prestazione:
-1.67%
1M Prestazione:
-1.84%
6M Prestazione:
-9.98%
1 anno Prestazione:
-24.53%
Intervallo 1D:
$52.38
$53.96
Intervallo di 1 settimana:
$51.56
$54.25
Portata 52W:
$51.56
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Nome
Biomarin Pharmaceutical Inc
Settore
Industria
Telefono
(415) 506-6700
Indirizzo
105 DIGITAL DRIVE, NOVATO, CA
Confronta BMRN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
52.95 | 10.08B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-08 | Iniziato | H.C. Wainwright | Neutral |
| 2025-09-03 | Iniziato | Raymond James | Outperform |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-02-24 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-30 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-20 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Iniziato | Evercore ISI | Outperform |
| 2023-11-15 | Iniziato | Wells Fargo | Overweight |
| 2023-10-23 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Iniziato | Raymond James | Mkt Perform |
| 2023-09-18 | Iniziato | UBS | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-07-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2023-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Iniziato | Citigroup | Neutral |
| 2023-01-30 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2022-10-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2022-04-25 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-09 | Aggiornamento | Stifel | Hold → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-04 | Ripresa | Guggenheim | Buy |
| 2021-03-01 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Downgrade | Stifel | Buy → Hold |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Reiterato | Citigroup | Buy |
| 2020-01-28 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-27 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-24 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-04-09 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Reiterato | Stifel | Buy |
| 2018-08-03 | Reiterato | Stifel | Buy |
Mostra tutto
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
How to read the order book for BioMarin Pharmaceutical Inc.Weekly Market Outlook & Precise Swing Trade Alerts - newser.com
What data driven models say about BioMarin Pharmaceutical Inc.’s future2025 Performance Recap & Community Trade Idea Sharing - newser.com
Achondroplasia Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | BioMarin Pharmaceuticals, BridgeBio/ QED Therapeutics, Ribomic Inc, Sanofi - The Globe and Mail
A Look at BioMarin Pharmaceutical’s Valuation as Revenue Growth and Pipeline Optimism Drive Investor Focus - Yahoo Finance
Real time social sentiment graph for BioMarin Pharmaceutical Inc.Swing Trade & Stock Market Timing Techniques - newser.com
What MACD signals say about BioMarin Pharmaceutical Inc.July 2025 Highlights & Real-Time Buy Signal Notifications - newser.com
Can BioMarin Pharmaceutical Inc. stock hit analyst price targetsJuly 2025 Drop Watch & Fast Moving Trade Plans - newser.com
Is BioMarin Pharmaceutical Inc. stock a safe buy before earnings2025 Historical Comparison & Weekly Setup with High ROI Potential - newser.com
Using flow based indicators on BioMarin Pharmaceutical Inc.July 2025 Opening Moves & Technical Buy Zone Confirmations - newser.com
BioMarin stock price target lowered to $80 at Cantor Fitzgerald By Investing.com - Investing.com Nigeria
BioMarin stock price target lowered to $80 at Cantor Fitzgerald - Investing.com
Price momentum metrics for BioMarin Pharmaceutical Inc. explainedJuly 2025 Gainers & Free Safe Entry Trade Signal Reports - newser.com
BioMarin Pharmaceutical Inc. stock outlook for YEAR2025 Geopolitical Influence & Proven Capital Preservation Methods - newser.com
Can BioMarin Pharmaceutical Inc. stock reach $100 price targetMarket Movement Recap & Weekly Market Pulse Alerts - newser.com
How to manage a losing position in BioMarin Pharmaceutical Inc.Long Setup & Weekly Setup with ROI Potential - newser.com
How strong is BioMarin Pharmaceutical Inc. stock balance sheetJuly 2025 PostEarnings & High Yield Stock Recommendations - newser.com
Understanding BioMarin Pharmaceutical Inc.’s price movementQuarterly Growth Report & Daily Oversold Stock Bounce Ideas - newser.com
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Eyeing an 82% Potential Upside Amid Robust Growth - DirectorsTalk Interviews
Ascendis Pharma Develops Sustained-Release Therapy to Compete with BioMarin’s Voxzogo for Achondroplasia Treatment - geneonline.com
Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause - BioSpace
Board of the Pension Protection Fund Invests $445,000 in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Aberdeen Group plc Has $54.04 Million Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
BioMarin Pharmaceutical (NASDAQ:BMRN) Sets New 12-Month LowTime to Sell? - MarketBeat
Leerink Partnrs Has Negative Outlook of BMRN Q1 Earnings - MarketBeat
Callan Family Office LLC Purchases 47,264 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens - MSN
Biomarin Pharmaceutical stock hits 52-week low at 52.47 USD By Investing.com - Investing.com Nigeria
10x Genomics, BioMarin Pharmaceutical, AMN Healthcare Services, Illumina, and Moderna Stocks Trade Down, What You Need To Know - TradingView
Biomarin Pharmaceutical stock hits 52-week low at 52.47 USD - Investing.com India
Relative strength of BioMarin Pharmaceutical Inc. in sector analysisQuarterly Investment Review & Community Trade Idea Sharing - newser.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $119.00 - MarketBeat
BioMarin Pharmaceutical's (BMRN) "Sell (D+)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Duchenne Muscular Dystrophy Drugs Market Global Forecast - GlobeNewswire
Biomarin Pharmaceutical Inc Azioni (BMRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):